Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.

Faruki H, Mayhew GM, Serody JS, Hayes DN, Perou CM, Lai-Goldman M.

J Thorac Oncol. 2017 Jun;12(6):943-953. doi: 10.1016/j.jtho.2017.03.010. Epub 2017 Mar 21.

2.

Validation of the Lung Subtyping Panel in Multiple Fresh-Frozen and Formalin-Fixed, Paraffin-Embedded Lung Tumor Gene Expression Data Sets.

Faruki H, Mayhew GM, Fan C, Wilkerson MD, Parker S, Kam-Morgan L, Eisenberg M, Horten B, Hayes DN, Perou CM, Lai-Goldman M.

Arch Pathol Lab Med. 2016 Jun;140(6):536-42. doi: 10.5858/arpa.2015-0113-OA. Epub 2015 Oct 2.

PMID:
26430809
3.

Implementation of a pharmacogenomics service in a community pharmacy.

Ferreri SP, Greco AJ, Michaels NM, O'Connor SK, Chater RW, Viera AJ, Faruki H, McLeod HL, Roederer MW.

J Am Pharm Assoc (2003). 2014 Mar-Apr;54(2):172-80. doi: 10.1331/JAPhA.2014.13033.

PMID:
24632932
4.

Cystic fibrosis carrier screening in a North American population.

Zvereff VV, Faruki H, Edwards M, Friedman KJ.

Genet Med. 2014 Jul;16(7):539-46. doi: 10.1038/gim.2013.188. Epub 2013 Dec 19.

PMID:
24357848
5.

Genomic testing: the clinical laboratory perspective.

Faruki H.

Clin Pharmacol Ther. 2013 Aug;94(2):190-2. doi: 10.1038/clpt.2013.61.

PMID:
23872833
6.

Making pharmacogenetic testing a reality in a community pharmacy.

O'Connor SK, Ferreri SP, Michaels NM, Chater RW, Viera AJ, Faruki H, McLeod HL, Roederer M.

J Am Pharm Assoc (2003). 2012;52(6):e259-65. doi: 10.1331/JAPhA.2012.12108.

PMID:
23229988
7.

Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy.

O'Connor SK, Ferreri SP, Michaels NM, Greco AJ, Viera AJ, Faruki H, McLeod HL, Roederer MW.

Pharmacogenomics. 2012 Jun;13(8):955-62. doi: 10.2217/pgs.12.67.

8.

Application of a pharmacogenetic test adoption model to six oncology biomarkers.

Faruki H, Lai-Goldman M.

Per Med. 2010 Jul;7(4):441-450. doi: 10.2217/pme.10.37.

PMID:
29788643
9.

Abacavir hypersensitivity: a model system for pharmacogenetic test adoption.

Lai-Goldman M, Faruki H.

Genet Med. 2008 Dec;10(12):874-8. doi: 10.1097/GIM.0b013e31818de71c. Review.

PMID:
19092439
10.

HLA-B*5701 screening for hypersensitivity to abacavir.

Faruki H, Lai-Goldman M.

Per Med. 2008 May;5(3):297-300. doi: 10.2217/17410541.5.3.297.

PMID:
29783490
11.

HLA-B*5701 clinical testing: early experience in the United States.

Faruki H, Heine U, Brown T, Koester R, Lai-Goldman M.

Pharmacogenet Genomics. 2007 Oct;17(10):857-60.

PMID:
17885623
12.

Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level.

Parikh UM, Barnas DC, Faruki H, Mellors JW.

J Infect Dis. 2006 Sep 1;194(5):651-60. Epub 2006 Jul 24.

PMID:
16897664
13.

Progression of liver fibrosis among injection drug users with chronic hepatitis C.

Wilson LE, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R, Mehta S, Kirk GD, Nelson K, Afdhal N, Thomas DL.

Hepatology. 2006 Apr;43(4):788-95.

PMID:
16557548
14.

Update on HIV resistance and resistance testing.

Sebastian J, Faruki H.

Med Res Rev. 2004 Jan;24(1):115-25. Review.

PMID:
14595674
15.

HIV resistance testing: methods, utility, and limitations.

Alcorn TM, Faruki H.

Mol Diagn. 2000 Sep;5(3):159-68. Review.

PMID:
11070150
16.

Arterial thromboembolic events in patients with the factor V Leiden mutation.

Eskandari MK, Bontempo FA, Hassett AC, Faruki H, Makaroun MS.

Am J Surg. 1998 Aug;176(2):122-5.

PMID:
9737615
17.

Peripheral retinal neovascularization (Eales disease) associated with the factor V Leiden mutation.

Eller AW, Bontempo FA, Faruki H, Hassett AC.

Am J Ophthalmol. 1998 Jul;126(1):146-9.

PMID:
9683168
18.

Heterosexual HIV-1 transmission and viral load in hemophilic patients.

Ragni MV, Faruki H, Kingsley LA.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jan 1;17(1):42-5.

PMID:
9436757
19.

Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B.

Van Thiel DH, Friedlander L, Kania RJ, Molloy PJ, Hassanein T, Wahlstrom E, Faruki H.

Hepatogastroenterology. 1997 May-Jun;44(15):808-12.

PMID:
9222695
20.

The factor V Leiden mutation: spectrum of thrombotic events and laboratory evaluation.

Bontempo FA, Hassett AC, Faruki H, Steed DL, Webster MW, Makaroun MS.

J Vasc Surg. 1997 Feb;25(2):271-5; discussion 276.

21.

A preliminary experience with GM-CSF plus interferon in patients with HBV and HCV resistant to interferon therapy.

Van Thiel DH, Friedlander L, Kania RJ, Molloy PJ, Hassanein T, Faruki H.

J Viral Hepat. 1997;4 Suppl 1:101-6.

PMID:
9097287
22.

New approach to HCV treatment. Recognition of disease process as systemic viral infection rather than as liver disease.

Friedlander L, van Thiel DH, Faruki H, Molloy PJ, Kania RJ, Hassanein T.

Dig Dis Sci. 1996 Aug;41(8):1678-81.

PMID:
8769301
23.

Combination treatment of advanced HCV associated liver disease with interferon and G-CSF.

Van Thiel DH, Faruki H, Friedlander L, Fagiuoli S, Caraceni P, Molloy PJ, Kania RJ, Wright HI.

Hepatogastroenterology. 1995 Nov-Dec;42(6):907-12.

PMID:
8847044
24.

Utility of hepatitis C virus RNA determinations in hepatic tissue as an end point for interferon treatment of chronic hepatitis C.

Gurakar A, Fagiuoli S, Faruki H, De Maria N, Balkan M, Van Thiel DH, Friedlander L.

Hepatology. 1995 Oct;22(4 Pt 1):1109-12.

PMID:
7557858
25.

Detection of cytomegalovirus in formalin-fixed paraffin-embedded donor, native and allograft liver tissue using a multiplex polymerase chain reaction-liquid hybridization assay.

Randhawa PS, Jaffe R, Faruki H, Rinaldo CR Jr, Ho M, Demetris AJ, Manez R, Kusne S, Ehrlich GD.

Mod Pathol. 1994 Jan;7(1):125-8.

PMID:
8159642
26.

Effect of calcium on in vitro activity of LY146032 against Clostridium difficile.

Faruki H, Niles AC, Heeren RL, Murray PR.

Antimicrob Agents Chemother. 1987 Mar;31(3):461-2.

27.
28.
29.
30.

Supplemental Content

Loading ...
Support Center